All Stories

Ferrer inks licensing deal worth up to €500M for Prilenia's ALS asset

Dutch biotech Prilenia Therapeutics has entered a licensing pact with Spanish pharmaceutical company Ferrer to push the biotech's sole asset through clinical development and beyond in Europe.

Apr 28, 2025 - 19:58
 0
Ferrer inks licensing deal worth up to €500M for Prilenia's ALS asset
Dutch biotech Prilenia Therapeutics has entered a licensing pact with Spanish pharmaceutical company Ferrer to push the biotech's sole asset through clinical development and beyond in Europe.
Read More

Tags:

Previous Article

U.S. Shoppers Turn To Buy Now, Pay Later For Groceries As High Costs Bite

Next Article

Cringe Reverse Discrimination Group Hijacks Michigan Law Listserv To Ask Student...

Related Posts

Fierce Biotech Layoff Tracker 2025: Caribou cuts 32% of staff; Mural lays off 90%

Fierce Biotech Layoff Tracker 2025: Caribou cuts 32% of...

Apr 25, 2025  0

Lowering blood pressure reduces dementia risk in patients with hypertension, large China trial reveals

Lowering blood pressure reduces dementia risk in patien...

Apr 24, 2025  0

Novo Holdings dials back investment as Trump stymies economic forecasters

Novo Holdings dials back investment as Trump stymies ec...

Apr 28, 2025  0